We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals

69.62 USD
-2.03
2.83%
At close Updated Nov 5, 4:00 PM EST
Pre-market
After hours
69.00
-0.62
0.89%
1 day
-2.83%
5 days
-4.98%
1 month
-4.08%
3 months
-12.84%
6 months
-17.74%
Year to date
-11.23%
1 year
-24.83%
5 years
39.18%
10 years
31.76%
 

About: ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Employees: 970

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 28.6%
Neutral 57.1%
Negative 14.3%
Negative
MarketBeat
12 hours ago
ANI Pharmaceuticals Q3 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.
ANI Pharmaceuticals Q3 Earnings Call Highlights
Positive
Zacks Investment Research
15 hours ago
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
16 hours ago
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
19 hours ago
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
19 hours ago
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
Neutral
GlobeNewsWire
1 day ago
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
Neutral
GlobeNewsWire
2 days ago
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
Neutral
GlobeNewsWire
13 days ago
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
Neutral
GlobeNewsWire
17 days ago
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
Positive
Zacks Investment Research
23 days ago
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Price charts implemented using Lightweight Charts™